Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

KW-2170 (Kyowa Hakko Kogyo).

Claire F Verschraegen1

  • 1UNM Cancer Research and Treatment Center, 900 Camino de Salud NE, Albuquerque, NM 87131, USA. cverschraegen@salud.unm.edu

Idrugs : the Investigational Drugs Journal
|June 12, 2003
PubMed
Summary

KW-2170, a novel pyrazoloacridone, is being investigated as a cancer treatment. This alkylating agent and topoisomerase II inhibitor has advanced to Phase II clinical trials for various cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report.

The oncologist·2026
Same author

Chemoprophylactic effect of PD-1/PD-L1 inhibitor treatment on non-melanoma skin cancer development.

Journal of the American Academy of Dermatology·2025
Same author

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.

Cancer investigation·2025
Same author

Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series.

Anticancer research·2025

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • KW-2170 is a pyrazoloacridone derivative with demonstrated alkylating agent and topoisomerase II inhibitory properties.
  • Kyowa Hakko Kogyo is developing KW-2170 as a potential therapeutic agent for various malignancies.

Purpose of the Study:

  • To evaluate the safety and efficacy of KW-2170 in cancer patients through clinical trials.
  • To advance the development of KW-2170 for the treatment of non-small-cell lung cancer, prostate cancer, colorectal cancer, ovarian cancer, and breast cancer.

Main Methods:

  • Phase I and Phase II clinical trials conducted in the US and Japan.
  • Regulatory submissions to the FDA for trial approval and anticipated New Drug Application (NDA).

Main Results:

  • KW-2170 entered Phase II trials in the US by December 2001.
  • Phase I trials in Japan were completed by August 2002.
  • Planned expansion of Phase II trials to multiple international locations.

Conclusions:

  • KW-2170 demonstrated sufficient promise to advance into Phase II clinical development.
  • The drug is being investigated for a range of solid tumors, with an anticipated NDA filing in 2006.

Related Experiment Videos